A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction.

[1]  M. Moriau,et al.  Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction. , 1989, The American journal of cardiology.

[2]  H. White,et al.  Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. , 1989, The New England journal of medicine.

[3]  L. Hillis,et al.  Do different doses of intravenous streptokinase alter the frequency of coronary reperfusion in acute myocardial infarction? , 1988, The American journal of cardiology.

[4]  Sol Sherry,et al.  Thrombolytic Therapy: Current Status , 1988 .

[5]  R. Califf,et al.  Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. , 1988, Annals of internal medicine.

[6]  F H Sheehan,et al.  The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.

[7]  S. Nelson,et al.  EVALUATION OF OPTIMUM STREPTOKINASE DOSAGE IN SYSTEMIC THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION: A RANDOMIZED TRIAL , 1987, Thrombosis and Haemostasis.

[8]  A. Six,et al.  Activation of the fibrinolytic system during intracoronary streptokinase administration. , 1987, Journal of the American College of Cardiology.

[9]  T. N. James,et al.  Report of WHO/ISFC Task Force on Nomenclature of Coronary Arteriograms. , 1986, Circulation.

[10]  P. Shah,et al.  The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction. , 1985, Circulation.

[11]  M. Simoons,et al.  IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION A Randomised Trial by the Interuniversity Cardiology Institute in The Netherlands , 1985, The Lancet.

[12]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[13]  E. Brommer.  The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. , 1984, Thrombosis research.

[14]  K. Wegscheider,et al.  Intravenous Short‐term Infusion of Streptokinase in Acute Myocardial Infarction , 1983, Circulation.

[15]  P. Gaffney,et al.  The influence of various combinations of plasminogen and streptokinase on fibrinolysis. II. A mechanistic study. , 1982, Haemostasis.

[16]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[17]  P. H. Bell,et al.  The mechanism of activation of human plasminogen by streptokinase. , 1971, Biochemical and biophysical research communications.